https://bnmgroup.advanzpharma.com/news/2025/advanz-pharma-acquires-global-rights-to-rare-disease-specialty-brand-zavesca2025-10-13https://bnmgroup.advanzpharma.com/news/2025/european-marketing-application-for-avt23-a-proposed-biosimilar-to-xolair-omalizumab-accepted-by-the-european-medicines-agency2025-10-06https://bnmgroup.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-three-additional-biosimilars-in-europe2025-05-28https://bnmgroup.advanzpharma.com/news/2025/advanz-pharma-and-pharmathen-expand-strategic-partnership-with-exclusive-license-and-supply-agreement2025-05-15https://bnmgroup.advanzpharma.com/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application-for-avt05-a-proposed-biosimilar-to-simponi-golimumab2024-11-04https://bnmgroup.advanzpharma.com/news/2024/advanz-pharma-releases-environmental-social-governance-esg-report-for-2023-20242024-10-04https://bnmgroup.advanzpharma.com/news/2024/advanz-pharma-and-enzene-enter-an-exclusive-partnership-for-biosimilar-development-and-commercialisation2024-08-27https://bnmgroup.advanzpharma.com/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept2024-08-15https://bnmgroup.advanzpharma.com/news/2024/alvotech-and-advanz-pharma-sign-commercialization-agreement-for-proposed-biosimilar-to-eylea-ld-hd-in-europe2024-06-18https://bnmgroup.advanzpharma.com/news/2024/advanz-pharma-and-allecra-therapeutics-announce-approval-in-the-european-union-for-the-new-antibiotic-combination-exblifep-cefepime-enmetazobactam-for-the-treatment-of-severe-infections2024-03-27https://bnmgroup.advanzpharma.com/news/2021/advanz-pharma-announces-launch-of-mytolac-in-germany-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22https://bnmgroup.advanzpharma.com/news/2021/advanz-pharma-announces-launch-of-myrelez-in-norway-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22https://bnmgroup.advanzpharma.com/news/2021/advanz-pharma-makes-key-changes-to-senior-leadership-to-further-accelerate-next-phase-of-growth2024-03-22https://bnmgroup.advanzpharma.com/news/2021/ne2024-03-22https://bnmgroup.advanzpharma.com/news/2024/advanz-pharma-receives-positive-chmp-opinion-for-exblifep-cefepime-enmetazobactam2024-01-26https://bnmgroup.advanzpharma.com/news/2023/advanz-pharma-and-dimerix-enter-into-an-exclusive-license-agreement-to-commercialise-dmx-200-in-europe-canada-australia-and-new-zealand2024-01-19https://bnmgroup.advanzpharma.com/news/2023/advanz-pharma-signs-an-exclusive-agreement-with-gp-pharm-for-a-peptide-specialty-injectable-generic-for-multiple-european-countries2024-01-19https://bnmgroup.advanzpharma.com/news/2023/advanz-pharma-releases-environmental-social-governance-esg-report-for-2022-20232024-01-19https://bnmgroup.advanzpharma.com/news/2023/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-five-proposed-biosimilars-in-europe2024-01-19https://bnmgroup.advanzpharma.com/news/2023/advanz-pharma-to-receive-exclusive-rights-from-applied-therapeutics-to-commercialise-at-007-govorestat-in-europe2024-01-19https://bnmgroup.advanzpharma.com/news/2022/advanz-pharma-further-strengthens-its-specialty-and-hospital-business-by-acquiring-an-anti-infective-portfolio-from-sanofi2024-01-19https://bnmgroup.advanzpharma.com/news/2022/advanz-pharma-to-receive-exclusive-rights-from-polypid-to-commercialize-d-plex100-in-europe2024-01-19https://bnmgroup.advanzpharma.com/news/2022/advanz-pharma-completes-acquisition-of-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19https://bnmgroup.advanzpharma.com/news/2022/advanz-pharma-to-acquire-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19https://bnmgroup.advanzpharma.com/news/2022/steffen-wagner-assumes-his-position-as-new-chief-executive-officer-at-advanz-pharma2024-01-19https://bnmgroup.advanzpharma.com/news/2022/cidron-aida-finco-s-%C3%A0-r-l-successful-pricing-of-175-0-million-5-senior-secured-notes-due-20282024-01-19https://bnmgroup.advanzpharma.com/news/2022/cidron-aida-finco-s-%C3%A0-r-l-proposed-offering-of-150-million-5-senior-secured-notes-due-20282024-01-19https://bnmgroup.advanzpharma.com/news/2022/allecra-therapeutics-and-advanz-pharma-sign-exclusive-license-and-supply-agreement-for-allecras-antibiotic-cefepime-enmetazobactam-in-europe2024-01-19https://bnmgroup.advanzpharma.com/news/2023/advanz-pharma-acquires-global-rights-to-androcur-from-bayer2024-01-19